Galapagos Q4 2022 Earnings Report $27.02 -0.10 (-0.37%) (As of 12:16 PM ET) Earnings HistoryForecast Galapagos EPS ResultsActual EPS-$1.99Consensus EPS -$1.90Beat/MissMissed by -$0.09One Year Ago EPSN/AGalapagos Revenue ResultsActual Revenue$97.15 millionExpected Revenue$110.08 millionBeat/MissMissed by -$12.93 millionYoY Revenue GrowthN/AGalapagos Announcement DetailsQuarterQ4 2022Date2/24/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseGLPG Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Galapagos Earnings HeadlinesGalapagos Struggles To Carve A Path In A Crowded CAR-T Therapy MarketDecember 14, 2024 | seekingalpha.comGalapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%December 13, 2024 | finance.yahoo.comWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!December 18, 2024 | DTI (Ad)Leerink Partnrs Weighs in on Galapagos FY2024 EarningsDecember 13, 2024 | americanbankingnews.comCautious Hold Rating for Galapagos: Unproven Efficacy and Logistical Concerns in CD19 CAR-T ProgramsDecember 11, 2024 | markets.businessinsider.comGalapagos Reports Promising CAR T-Cell Therapy ResultsDecember 9, 2024 | markets.businessinsider.comSee More Galapagos Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Galapagos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galapagos and other key companies, straight to your email. Email Address About GalapagosGalapagos (NASDAQ:GLPG), a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.View Galapagos ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
